Skip to main content

Laura Horst Rosenberger

Associate Professor of Surgery
Surgical Oncology
Duke University Medical Center, Box 3513, Durham, NC 27710

Overview


Dr. Laura Rosenberger is an Associate Professor of Surgery, where she has a high-volume breast surgical oncology practice and enjoys all aspects of an academic career. She has clinical expertise and research interest in rare breast cancers, including sarcomas and a specific focus on phyllodes tumors. Dr. Rosenberger is the founding and coordinating Principal Investigator of multiple, multi-institutional studies, including a funded prospective germline testing study, and an actively accruing rare breast tumor registry with tissue biorepository. She has authored, or co-authored, over 75 peer-reviewed publications, and serves on multiple national committees including a member of the National Comprehensive Cancer Network, or NCCN, Breast Cancer Panel.  

Current Appointments & Affiliations


Associate Professor of Surgery · 2021 - Present Surgical Oncology, Surgery
Member of the Duke Cancer Institute · 2019 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published February 25, 2025
New Understanding for a Rare Breast Tumor from Duke Cancer Institute Researchers

View All News

Recent Publications


Locally Ablative Therapies in Oligometastatic Breast Cancer.

Journal Article JAMA Surg · March 4, 2026 IMPORTANCE: Management of de novo metastatic breast cancer (dnMBC) often focuses on palliation. As such, the potential survival benefit of surgery or ablative therapy remains unclear, particularly for those with oligometastatic disease. OBJECTIVE: To evalu ... Full text Link to item Cite

Radiation De-Escalation in Older Women with Early-Stage ER+/HER2- Invasive Breast Cancer.

Journal Article Ann Surg Oncol · March 2026 BACKGROUND: National recommendations since 2004 have allowed for omission of post-lumpectomy radiotherapy for patients ≥70 years old with early-stage estrogen receptor positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. ... Full text Link to item Cite
View All Publications

Recent Grants


Defining Actionable Opportunities in Malignant Phyllodes via Genomic Profiling

ResearchPrincipal Investigator · Awarded by Food and Drug Administration · 2024 - 2027

View All Grants

Education


University of Virginia · 2011 M.S.
Thomas Jefferson University, Sidney Kimmel Medical College · 2008 M.D.
Eastern Mennonite University · 2003 B.S.